Table 4.
Group | New bone in gap | |||
---|---|---|---|---|
Control | Low dose | Middle dose | High dose | |
Control | — | — | — | — |
Low dose | 0.013 | — | — | — |
Middle dose | 0.54 | 0.0050 | — | — |
High dose | 0.0076 | 0.0076 | 0.013 | — |
Allograft in gap | ||||
---|---|---|---|---|
Control | Low dose | Middle dose | High dose | |
Control | — | — | — | — |
Low dose | 0.0050 | — | — | — |
Middle dose | 0.0050 | 0.0059 | — | — |
High dose | 0.0076 | 0.0075 | 0.21 | — |
New bone on implant surface | ||||
---|---|---|---|---|
Control | Low dose | Middle dose | High dose | |
Control | — | — | — | — |
Low dose | 0.079 | — | — | — |
Middle dose | 0.15 | 1.00 | — | — |
High dose | 0.0089 | 0.012 | 0.048 | — |
Allograft on implant surface | ||||
---|---|---|---|---|
Control | Low dose | Middle dose | High dose | |
Control | — | — | — | — |
Low dose | 0.74 | — | — | — |
Middle dose | 0.012 | 0.011 | — | — |
High dose | 0.0075 | 0.0075 | 0.23 | — |
Friedman’s analysis followed by Wilcoxon signed rank test.